A Phase III Study of Chemoradiotherapy with or without Atezolizumab for Patients with Localized Muscle-Invasive Bladder Cancer


Full Title

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer (S1806) (CIRB)


The purpose of this study is to see how well chemotherapy and radiation therapy work with or without atezolizumab to treat patients with localized muscle-invasive bladder cancer. Giving chemotherapy with radiation therapy may kill more tumor cells than either treatment alone. Atezolizumab is an immunotherapy that boosts the ability of the immune system to find and kill cancer cells.

Giving atezolizumab with radiation therapy and chemotherapy may work better against localized muscle-invasive bladder cancer than radiation therapy and chemotherapy without atezolizumab. Patients in this study will be randomly assigned to receive radiation therapy and chemotherapy with or without atezolizumab. Chemotherapy and atezolizumab are given intravenously (by vein).

Who Can Join

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have localized (not metastatic) bladder cancer that has grown into the muscle wall and is surgically removed within 70 days of entering the study.
  • Patients may not have received prior chemotherapy, immunotherapy, or radiation therapy for their bladder cancer.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Marisa Kollmeier at 212-639-3952.